3-羟基-5-(1h)吲唑羧酸 | 787580-93-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 3-羟基-5-(1h)吲唑羧酸
• 中文别名: 3-氧代-2,3-二氢-1氢-吲唑-5-羧酸
• 英文名称: 3-oxo-2,3-dihydro-1H-indazole-5-carboxylic acid
• 英文别名: 3-oxo-1,2-dihydroindazole-5-carboxylic acid
• CAS: 787580-93-2
• 化学式: C₈H₆N₂O₃
• mdl: MFCD07781586
• 分子量: 178.147
• InChiKey: JAPGBCYHMJSRNG-UHFFFAOYSA-N

物化性质

• 熔点：
  >251°C (dec.)
• 沸点：
  362.4±21.0 °C(Predicted)
• 密度：
  1.489±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.4
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  3-羟基-5-(1h)吲唑羧酸 在 N-甲基吡咯烷酮 、 五氟苯酚 、 potassium carbonate 、 caesium carbonate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 21.5h， 生成
  参考文献：
  名称：

  Discovery of phenoxyindazoles and phenylthioindazoles as RORγ inverse agonists

  摘要：

  Targeting the IL17 pathway and more specifically the nuclear receptor ROR gamma is thought to be beneficial in multiple skin disorders. The Letter describes the discovery of phenoxyindazoles and thiophenoxy indazoles as potent ROR gamma inverse agonists. Optimization of the potency and efforts to mitigate the phototoxic liability of the series are presented. Finally, crystallization of the lead compound revealed that the series bound to an allosteric site of the nuclear receptor. Such compounds could be useful as tool compounds for understanding the impact of topical treatment on skin disease models. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.10.023
• 作为产物：
  描述：

  3-氧代-1,2-二氢吲唑-5-羧酸甲酯 在 lithium hydroxide monohydrate 、 水 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 16.0h， 生成 3-羟基-5-(1h)吲唑羧酸
  参考文献：
  名称：

  Discovery of phenoxyindazoles and phenylthioindazoles as RORγ inverse agonists

  摘要：

  Targeting the IL17 pathway and more specifically the nuclear receptor ROR gamma is thought to be beneficial in multiple skin disorders. The Letter describes the discovery of phenoxyindazoles and thiophenoxy indazoles as potent ROR gamma inverse agonists. Optimization of the potency and efforts to mitigate the phototoxic liability of the series are presented. Finally, crystallization of the lead compound revealed that the series bound to an allosteric site of the nuclear receptor. Such compounds could be useful as tool compounds for understanding the impact of topical treatment on skin disease models. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.10.023

文献信息

• N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS
  申请人：Griffith David A.

  公开号：US20120108619A1

  公开（公告）日：2012-05-03

  The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R 1 , R 2 and R 3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

  这项发明提供了化合物的化学式(I)或其药用可接受的盐；其中G是R1，R2和R3如本文所述；以及其药物组合物；以及在治疗受乙酰辅酶A羧化酶抑制调节的动物疾病、状况或紊乱中的使用。
• [EN] 3-OXO-1, 3-DIHYDRO-INDAZOLE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS PHOSPHOLIPASE INHIBITORS<br/>[FR] UTILISATION DE DERIVES AMIDES D'ACIDE 3-OXO-1,3-DIHYDRO-INDAZOLE-2-CARBOXYLIQUE COMME INHIBITEURS DE LA PHOSPHOLIPASE
  申请人：LILLY CO ELI

  公开号：WO2004093872A1

  公开（公告）日：2004-11-04

  The present invention provides a compound of formula I (1) wherein; R, is selected from the group consisting of C5-C13alky1;:C,-C,2haloalkyl, C4­C,2alkenyl, C4-C12alkynyl, or C,- C5alkylcycloalkyl, C3-C8cycloalkyl, C,­ C5alkylheterocyclic, and aryl, wherein the, cycloalkyl, cycloalkenyl, heterocyclic and aryl substituents are optionally substituted with onf to three substituents independently selected from C,-C8a)kyl, C,-C8haloalkyl,`C2-CBalkenyl, C2-C8a)kynyl, phenyl, benzyl, hydroxy, C,-C5 alkoxy, (C}12)m000C,-Csalkyl, (CH2)mNRaRb, and C,­C4alkylcycloalkyl; wherein Wand Rb are independently selected from hydrogen, C,­CBalkyl, C2-CBalkenyl, C2-CBalkynyl, and C,- C5alkylcycloalkyl; R2 is hydrogen; R3, R4, R5, and R6, are independently selected from hydrogen, C,-C12alkyl, C2­C,2haloalkyl, C2-C,2 alkenyl, C2-C12alkynyl, C,-Ct2alkylaryl, C,-C12alkylcyclohexyl, C,­ C12alkylcyclopentyl, C,-C1zalkylheterocyclic, (CH2)m000H, (CH2)mC0(C,-C,o)alkyl, (CH2)m COO(C,-C,o)alkyl, (CH2)mCOO(C,-C,o)alkylaryl, C,-C,oalkylamino, halo, (CH2)mCONH2, (CH2)rCONRaRb, phenyl, or aryl wherein each of the phenyl or aryl groups is optionally substituted with one to three groups independently selected from CBalkyl, C,-CBhaloalkyl, C2-CBalkenyl, CZ CBalkynyl, phenyl, benzyl, hydroxy, C,-C5 alkoxy, (CH2)m000C,-Csalkyl, and C,-C4alkylcycloalkyl; and wherein m is 0, 1, 2, or 3; R7 is selected from the group consisting of hydrogen, C,-Cloalkyl, C,­C,ohaloalkyl, C2-C,oalkenyl, C2-C,oalkynyl, C,-C6alkylaryl, C,-C6alkylcyclohexyl, C - C6aikylcyclopentyl, C,-C6alkylheterocyclic, or aryl; or a pharmaceutically acceptable sal lvate thereofi together with the use of such compounds for inhibiting hepatic lipase and/or endothelial lipase activity for treatment, amelioration or prevention of hepatic lipase and/or endothelial lipase-mediated diseases.

  本发明提供了一种式子I（1）的化合物，其中R选自C5-C13烷基，C3-C12卤代烷基，C4-C12烯基，C4-C12炔基，或C1-C5烷基环烷基，C3-C8环烷基，C1-C5烷基杂环，和芳基，其中环烷基，环烯基，杂环和芳基取代基可选择地独立地被C1-C8烷基，C1-C8卤代烷基，C2-C8烯基，C2-C8炔基，苯基，苄基，羟基，C1-C5烷氧基，（C12）m000C1-C5烷基，（CH2）mNRaRb和C1-C4烷基环烷基取代，其中W和Rb独立地选择氢，C1-C6烷基，C2-C6烯基，C2-C6炔基和C1-C5烷基环烷基；R2为氢；R3、R4、R5和R6独立地选择氢，C1-C12烷基，C2-C12卤代烷基，C2-C12烯基，C2-C12炔基，C1-C12烷基芳基，C1-C12烷基环己基，C1-C12烷基环戊基，C1-C12烷基杂环，（CH2）m000H，（CH2）mCO（C1-C4）烷基，（CH2）mCOO（C1-C4）烷基，（CH2）mCOO（C1-C4）烷基芳基，C1-C4烷基氨基，卤素，（CH2）mCONH2，（CH2）rCONRaRb，苯基或芳基，其中苯基或芳基中的每个取代基可选择地独立地被C1-C8烷基，C1-C8卤代烷基，C2-C8烯基，C2-C8炔基，苯基，苄基，羟基，C1-C5烷氧基，（C12）m000C1-C5烷基和C1-C4烷基环烷基取代；其中m为0、1、2或3；R7选自氢，C1-C6烷基，C1-C6卤代烷基，C2-C6烯基，C2-C6炔基，C1-C6烷基芳基，C1-C6烷基环己基，C1-C6烷基环戊基，C1-C6烷基杂环或芳基；或其药学上可接受的盐；以及使用这样的化合物来抑制肝脏脂肪酶和/或内皮脂肪酶活性，用于治疗、缓解或预防肝脏脂肪酶和/或内皮脂肪酶介导的疾病。
• 3-oxo-1, 3-dihydro-indazole-2-carboxylic acid amide derivatives as phospholipase inhibitors
  申请人：Eacho Irving Patrick

  公开号：US20060211755A1

  公开（公告）日：2006-09-21

  The present invention provides a compound of formula I (1) wherein; R, is selected from the group consisting of C 5 -C 13 alkyl; C,—C, 2 haloalkyl, C 4 C,2alkenyl, C 4 -C 12 alkynyl, or C,—C5alkylcycloalkyl, C3-C8cycloalkyl, C, C 5 alkylheterocyclic, and aryl, wherein the, cycloalkyl, cycloalkenyl, heterocyclic and aryl substituents are optionally substituted with one to three substituents independently selected from C,—C 8 a)kyl, C,—C 8 haloalkyl, ′C 2 -C B alkenyl, C2-C 8 a)kynyl, phenyl, benzyl, hydroxy, C,—C5 alkoxy, (C}12) m 000C,—Csalkyl, (CH2) m NR a R b , and C,C 4 alkylcycloalkyl; wherein W and R b are independently selected from hydrogen, C,C B alkyl, C 2 -C B alkenyl, C 2 -C B alkynyl, and C,—C5alkylcycloalkyl; R 2 is hydrogen; R3, R4, R5, and R6, are independently selected from hydrogen, C,—C 12 alkyl, C 2 C,2haloalkyl, C2-C,2 alkenyl, C 2 -C 12 alkynyl, C,—C 12 alkylaryl, C,—C 12 alkylcyclohexyl, C, C 12 alkylcyclopentyl, C,—C 12 alkylheterocyclic, (CH2) m 000H, (CH2) m C0(C,—C,o)alkyl, (CH 2 ) m COO(C,—C ,o )alkyl, (CH2) m COO(C 1 -C ,o )alkylaryl, C,—C ,o alkylamino, halo, (CH 2 ) m CONH 2 , (CH 2 ) r CONRaR b , phenyl, or aryl wherein each of the phenyl or aryl groups is optionally substituted with one to three groups independently selected from C B alkyl, C,—C B haloalkyl, C 2 -C B alkenyl, C Z C B alkynyl, phenyl, benzyl, hydroxy, C,—C5 alkoxy, (CH2) m 000C,—Csalkyl, and C,—C4alkylcycloalkyl; and wherein m is 0, 1, 2, or 3; R7 is selected from the group consisting of hydrogen, C,—C lo alkyl, C,C ,o haloalkyl, C 2 -C ,o alkenyl, C 2 -C ,o alkynyl, C,—C 6 alkylaryl, C,—C 6 alkylcyclohexyl, C—C 6 aikylcyclopentyl, C,—C 6 alkylheterocyclic, or aryl; or a pharmaceutically acceptable sallvate thereofi together with the use of such compounds for inhibiting hepatic lipase and/or endothelial lipase activity for treatment, amelioration or prevention of hepatic lipase and/or endothelial lipase-mediated diseases.

  本发明提供一种公式I（1）的化合物，其中：R选自C5-C13烷基；C，C2卤代烷基，C4-C2烯基，C4-C12炔基，或C，C5烷基环烷基，C3-C8环烷基，C，C5烷基杂环基和芳基，其中环烷基，环烯基，杂环和芳基取代基可选地独立地被选自C，C8烷基，C，C8卤代烷基，C2-CB烯基，C2-C8炔基，苯基，苄基，羟基，C，C5烷氧基，（C}12）m000C，C5烷基，（CH2）mNRaRb和C，C4烷基环烷基的一个到三个取代基所取代；其中W和Rb独立地选自氢，C，C8烷基，C2-CB烯基，C2-CB炔基和C，C5烷基环烷基；R2为氢；R3，R4，R5和R6独立地选自氢，C，C12烷基，C2-C，2卤代烷基，C2-C，2烯基，C2-C12炔基，C，C12烷基芳基，C，C12烷基环己基，C，C12烷基环戊基，C，C12烷基杂环基，（CH2）m000H，（CH2）mC0（C，C，o）烷基，（CH2）mCOO（C，C，o）烷基，（CH2）mCOO（C1-C，o）烷基芳基，C，C，o烷基氨基，卤素，（CH2）mCONH2，（CH2）rCONRaRb，苯基或芳基，其中苯基或芳基中的每个苯基或芳基可选地独立地被选自C烷基，C，C卤代烷基，C2-CB烯基，CZCB炔基，苯基，苄基，羟基，C，C5烷氧基，（CH2）m000C，C5烷基和C，C4烷基环烷基的一个到三个基团所取代；其中m为0、1、2或3；R7选自氢，C，C6烷基，C，C6卤代烷基，C2-C，o烯基，C2-C，o炔基，C，C6烷基芳基，C，C6烷基环己基，C-C6烷基环戊基，C，C6烷基杂环基或芳基；或其药学上可接受的盐；以及使用这种化合物来抑制肝脏脂酶和/或内皮脂酶活性，用于治疗、改善或预防肝脏脂酶和/或内皮脂酶介导的疾病。
• N1/N2-lactam acetyl-CoA carboxylase inhibitors
  申请人：Griffith David A.

  公开号：US08859773B2

  公开（公告）日：2014-10-14

  The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

  本发明提供了一种公式（I）的化合物或其药学上可接受的盐；其中G为R1，R2和R3如本文所述；其药物组成物；以及在治疗动物中由乙酰辅酶A羧化酶酶抑制调节的疾病，状况或障碍中使用它的用途。
• EP1610779A1
  申请人：——

  公开号：EP1610779A1

  公开（公告）日：2006-01-04